2025 GU ASCO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. Highlights in this video include: • TALAPRO-2: Talazoparib + Enzalutamide improves OS in mCRPC with significant enrichment in HRR population • ENZA-P: 177LuPSMA + Enzalutamide improves rPFS, OS and QOL in mCRPC • WOLVERINE: Meta-analysis demonstrates benefit of metastasis-directed therapy in oligometastatic prostate cancer
▶︎
AUA Advanced Prostate Cancer Course Webcast (2025)
▶︎
2025 Update on Prostate Cancer
▶︎
Baim Grand Rounds Katherine Tuttle 15Jun2026
▶︎
2025 GU ASCO Bladder Cancer Highlights
▶︎
New Advances in Prostate Cancer in 2025
▶︎
Baim Grand Rounds Manesh Patel 08Jun2026
▶︎
Surgery or Radiotherapy for Prostate Cancer? Here's What the Evidence Shows
▶︎
Prostate Cancer Management from Early Stage to Advanced Metastatic Disease - Dr. Alan Bryce
▶︎
Advanced Pancreatic Cancer Treatments in 2026: What you need to know.
▶︎
ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04
▶︎
Prostate Cancer Diagnosis: AUA Guidelines on use of PSA Biomarkers, MRI and Biopsy Techniques (2024)
▶︎
Prostate Cancer Breakthroughs: Updates from the 2025 ASCO Annual Meeting | ZERO Prostate Cancer
▶︎
Advanced Treatments in 2025 Eugene Kwon, MD | DIY Combat Manual for Beating Prostate Cancer Part 7
▶︎
Overview of Clinical Trials from Young-Onset Colorectal Cancer Center | Dana-Farber Cancer Institute
▶︎
Hepatology and Liver Transplantation Webinar | MASLD Highlights 2026
▶︎
2026.06.15 ACVNU Journal Club (Aly Fitzgerald)
▶︎
Radiation therapy for prostate cancer: the basics
▶︎
Risk Assessment of PSA Recurrent Prostate Cancer
▶︎
Core Curriculum - CCS Heart Failure with non-reduced EF Guidelines 2025: a Review
▶︎